358 related articles for article (PubMed ID: 17016600)
1. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
Zhang JY; Casiano CA; Peng XX; Koziol JA; Chan EK; Tan EM
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):136-43. PubMed ID: 12582023
[TBL] [Abstract][Full Text] [Related]
4. Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer.
Li J; Wang LJ; Ying X; Han SX; Bai E; Zhang Y; Zhu Q
Scand J Immunol; 2012 Mar; 75(3):342-9. PubMed ID: 22010875
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer.
Liu W; Wang P; Li Z; Xu W; Dai L; Wang K; Zhang J
Scand J Immunol; 2009 Jan; 69(1):57-63. PubMed ID: 19140877
[TBL] [Abstract][Full Text] [Related]
6. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis.
Koziol JA; Zhang JY; Casiano CA; Peng XX; Shi FD; Feng AC; Chan EK; Tan EM
Clin Cancer Res; 2003 Nov; 9(14):5120-6. PubMed ID: 14613989
[TBL] [Abstract][Full Text] [Related]
7. Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma.
Zhou SL; Yue WB; Fan ZM; Du F; Liu BC; Li B; Han XN; Ku JW; Zhao XK; Zhang P; Cui J; Zhou FY; Zhang LQ; Fan XP; Zhou YF; Zhu LL; Liu HY; Wang LD
Dis Esophagus; 2014; 27(8):790-7. PubMed ID: 24147952
[TBL] [Abstract][Full Text] [Related]
8. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis.
Zhang JY
Cancer Detect Prev; 2004; 28(2):114-8. PubMed ID: 15068835
[TBL] [Abstract][Full Text] [Related]
10. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
11. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
[TBL] [Abstract][Full Text] [Related]
12. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.
Zhang JY; Megliorino R; Peng XX; Tan EM; Chen Y; Chan EK
J Hepatol; 2007 Jan; 46(1):107-14. PubMed ID: 17067715
[TBL] [Abstract][Full Text] [Related]
13. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.
Burnworth B; Arendt S; Muffler S; Steinkraus V; Bröcker EB; Birek C; Hartschuh W; Jauch A; Boukamp P
Eur J Cell Biol; 2007 Dec; 86(11-12):763-80. PubMed ID: 17198740
[TBL] [Abstract][Full Text] [Related]
14. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients.
Rohayem J; Diestelkoetter P; Weigle B; Oehmichen A; Schmitz M; Mehlhorn J; Conrad K; Rieber EP
Cancer Res; 2000 Apr; 60(7):1815-7. PubMed ID: 10766164
[TBL] [Abstract][Full Text] [Related]
15. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma.
Himoto T; Kuriyama S; Zhang JY; Chan EK; Kimura Y; Masaki T; Uchida N; Nishioka M; Tan EM
Int J Oncol; 2005 Oct; 27(4):1079-85. PubMed ID: 16142326
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle dysregulation influences survival in high risk breast cancer patients.
Königsberg R; Rögelsperger O; Jäger W; Thalhammer T; Klimpfinger M; De Santis M; Hudec M; Dittrich C
Cancer Invest; 2008 Aug; 26(7):734-40. PubMed ID: 18665474
[TBL] [Abstract][Full Text] [Related]
17. Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
DeInnocentes P; Agarwal P; Bird RC
J Cell Biochem; 2009 Feb; 106(3):491-505. PubMed ID: 19130492
[TBL] [Abstract][Full Text] [Related]
18. Identification of HCC-22-5 tumor-associated antigen and antibody response in patients.
Zhou SF; Xie XX; Bin YH; Lan L; Chen F; Luo GR
Clin Chim Acta; 2006 Apr; 366(1-2):274-80. PubMed ID: 16356486
[TBL] [Abstract][Full Text] [Related]
19. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
[TBL] [Abstract][Full Text] [Related]
20. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
Sakai H
Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
